RxDoctor Payments Data

Kristin Torre, MD

Dermatology · Oxford, CTNPI 1760944896

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (54.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Incyte Corporation at 46.9% of the total. 2025 is the largest year on record at $16,234, more than ten times the $1,068 reported in 2023.

$20,400in general payments, 2019–2025

Across 386 payments — averaging $52.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$10K
  • Arcutis Biotherapeutics, Inc.$4K
  • AbbVie$2K
  • Johnson & Johnson$995
  • Regeneron Healthcare Solutions, Inc.$727
  • UCB, Inc.$516
  • plus $3K from 17 others

What the payments were for

  • Consulting fees$11,05054%
  • Travel & lodging$9625%
  • Food & beverage$7,95439%
  • Education$4352%

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,400 in reported general payments places this provider in the 85th percentile of 222 dermatology providers in Connecticut.

See all dermatology providers in Connecticut

Medicare billing

Part B allowed, 2024
$91,969
Medicare patients
321
Services billed
1,412

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab39$162,308
ZoryveRoflumilast11$9,725
Clobetasol Propionate137$5,071
Tacrolimus21$2,848
Doxycycline Hyclate59$1,438
Metronidazole30$1,183
Fluorouracil18$1,055
Clindamycin Phosphate28$852
Nystatin38$790
Triamcinolone Acetonide102$662
Ketoconazole58$651
Mupirocin50$358
Hydrocortisone75$307
Betamethasone Dipropionate12$220

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Arcutis Biotherapeutics, Inc.Zoryve$3,631$9,72511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 222 dermatology providers in Connecticut.

Other dermatology in Oxford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →